Bayer justifies Brandicourt’s ‘golden handshake’
February 27, 2015Medical Communications, Sales and Marketing Bayer, CEO, Sanofi, dekkers, olivier brandicourt, payments, wages
Bayer has confirmed that Sanofi’s justification for the controversial starter package it is giving to the German firm’s Olivier Brandicourt …
Most Americans ready for health wearables and apps
February 27, 2015Medical Communications, Sales and Marketing Makovsky/Kelton, Pulse of Online Health, US, app, apps, digital, wearables
Americans are ready and willing to leverage health apps and wearable devices in order to improve their personal health according …
Bayer MaterialScience gets new chairman
February 27, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Oliver Brandicourt, Werner Baumann, richard pott
Dr Richard Pott has been appointed to the supervisory board at Bayer MaterialScience as its new chairman. Pott replaces Werner …
GlaxoSmithKline announces board changes early
February 26, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, GlaxoSmithKline, Tom de Swaan, christopher gent, sir philip hampton
GlaxoSmithKline has confirmed that Sir Christopher Gent will step down early as chairman of GSK in May to be succeeded …
New drugs give Bayer record sales
February 26, 2015Sales and Marketing Bayer, Eylea, Radium-223 chloride, Stivarga, Xarelto, adempas, aflibercept, dekkers, german, regorafenib, riociguat, xofigo
Bayer has reported strong financial results for 2014 driven primary by sales of new medicines, although controversy surrounding its anti-clotting …
Sanofi sees FDA approval for diabetes drug
February 26, 2015Sales and Marketing Afrezza, FDA, Q2, Sanofi, Twitter, diabetes, insulin glargine, q4
US regulators have approved Sanofi’s diabetes treatment Toujeo which is said to be a follow-up to the French firms key …
GenMark Diagnostics performs board shuffle
February 26, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing genmark diagnostics, lisa giles, michael kagnoff
US diagnostic systems provider GenMark Diagnostics has named two new board members whilst announcing a resignation. Lisa Giles (pictured) who …
Eisai cancer drug performs in sarcoma disease
February 26, 2015Sales and Marketing Cancer, Eisai, Halaven, eribulin, sarcoma, tumour
Eisai’s cancer drug Halaven met its primary endpoint and demonstrated overall survival benefit in two distinct solid tumour types in …
AstraZeneca enters autoimmune diseases pact with Orca
February 25, 2015Research and Development, Sales and Marketing AstraZeneca, autoimmune, orca, orphan nuclear receptor gamma inhibitors, psoriasis, retinoic
AstraZeneca has signed a three-year research deal with the UK-based biotech firm Orca to develop treatments for autoimmune diseases. The …
Napp launches biosimilar in UK
February 25, 2015Research and Development, Sales and Marketing Hospira, Napp, Remicade, anti-TNF biologic, biosimilar, infliximab, remsima
Napp Pharmaceuticals has launched its own biosimilar version of an anti-TNF biologic in Europe paving the way for patient access …
Gilead frustrated despite final NICE Sovaldi nod
February 25, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, sofosbuvir, sovaldi
NICE has published final guidance confirming its approval of Gilead’s controversial blockbuster hepatitis C treatment Sovaldi – but Gilead and …
UCB’s new chief executive picked as EU rep for MISG
February 25, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jean-Christophe Tellier, MISG, UCB
UCB’s newly-appointed chief executive Jean-Christophe Tellier has been selected to join the Ministerial Industry Strategy Group (MISG). Elected to the …
Shire to buy Meritage Pharma
February 25, 2015Research and Development, Sales and Marketing AbbVie, Meritage Pharma, Shire, eoe, gastrointestinal
Shire has purchased Meritage Pharma, a privately-held company specialising in gastrointestinal and skin diseases for $70 million. The acquisition means …
Doctors appeal to prescribe Avastin off-label
February 25, 2015Sales and Marketing Lucentis, NHS, NICE, Novartis, Roche, bevacizumab, wet AMD
NHS Clinical Commissioners have called for the removal of barriers preventing CCGs from prescribing Roche’s Avastin to treat wet age-related …
FDA in Novartis cancer drug U-turn
February 24, 2015Research and Development, Sales and Marketing Cancer, FDA, Farydak, Novartis, Revlimid, Velcade, myeloma
The FDA has overturned an earlier advisory committee recommendation and decided to approve Novartis’ blood cancer drug Farydak. In November …
Takeda acquires Turkish firm Neutec
February 24, 2015Sales and Marketing Takeda, Turkey, gastroenterology, neutec, respiratory, turkish
Takeda has signed an agreement to acquire one of Turkey’s leading pharma firms Neutec in a $120 million deal. The …
Merck puts HIV drug in shared patent pool
February 24, 2015Research and Development, Sales and Marketing AbbVie, Gilead, HIV, Merck, Raltegravir, Roche, isentress
Merck is teaming up with the Medicines Patent Pool (MPP) to license its paediatric HIV treatment in developing countries. The …
Novel device could help fight kidney disease
February 24, 2015Research and Development, Sales and Marketing Bio Nano Consulting, Pfizer, QELFA, Rapamune, device, ime, kidney
A novel device that combines nanotechnology and a pregnancy tester could help treat kidney disease, according to a report by …
BMS in $1.5 billion immuno-oncology expansion
February 24, 2015Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Rigel, flexus, immuno-oncology
Bristol-Myers Squibb has confirmed two major deals to enhance the company’s standing in the immuno-oncology field. The first agreement sees …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
